Clinical characteristics of meningiomas assessed by 11C- methionine and 18F-fluorodeoxyglucose positron-emission tomography

Journal of Neuro-Oncology

Volumn 107, Issue 2, 2012, Pages 379-386

  Arita, Hideyuki ^a   Kinoshita, Manabu ^a   Okita, Yoshiko ^a   Hirayama, Ryuichi ^a   Watabe, Tadashi ^a   Ishohashi, Kayako ^a   Kijima, Noriyuki ^a   Kagawa, Naoki ^a   Fujimoto, Yasunori ^a   Kishima, Haruhiko ^a   Shimosegawa, Eku ^a   Hatazawa, Jun ^a   Hashimoto, Naoya ^a   Yoshimine, Toshiki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Meningioma; Methionine; Positron emission tomography; Volume

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHIONINE C 11; CARBON; DIAGNOSTIC AGENT; METHIONINE;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER GRADING; CANCER GROWTH; CANCER SIZE; CANCER SURGERY; CLINICAL FEATURE; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; FUNCTIONAL NEUROIMAGING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MICROVESSEL DENSITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; TUMOR NORMAL RATIO; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; CARBON ISOTOPES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; METHIONINE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84862316849     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0759-2     Document Type: Article

References (34)

1. Hashiba T, Hashimoto N, Izumoto S, Suzuki T, Kagawa N, Maruno M, Kato A, Yoshimine T (2009) Serial volumetric assessment of the natural history and growth pattern of incidentally discovered meningiomas. J Neurosurg 110:675-684
2. Nakasu S, Fukami T, Nakajima M, Watanabe K, Ichikawa M, Matsuda M (2005) Growth pattern changes of meningiomas: long-term analysis. Neurosurgery 56:946-955 discussion 946-955
3. Kallio M, Sankila R, Hakulinen T, Jaaskelainen J (1992) Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery 31:2-12
4. Kane AJ, Sughrue ME, Rutkowski MJ, Shangari G, Fang S, McDermott MW, Berger MS, Parsa AT (2011) Anatomic location is a risk factor for atypical and malignant meningiomas. Cancer 117:1272-1278
5. Nakasu S, Nakasu Y, Nakajima M, Matsuda M, Handa J (1999) Preoperative identification of meningiomas that are highly likely to recur. J Neurosurg 90:455-462
6. Lee JW, Kang KW, Park SH, Lee SM, Paeng JC, Chung JK, Lee MC, Lee DS (2009) 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging 36:1574-1582
7. De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, Salmon I, Brotchi J, Goldman S (2001) Positron-emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95:746-750
8. Kaminogo M, Ishimaru H, Morikawa M, Ochi M, Ushijima R, Tani M, Matsuo Y, Kawakubo J, Shibata S (2001) Diagnostic potential of short echo time MR spectroscopy of gliomas with single-voxel and point-resolved spatially localised proton spectroscopy of brain. Neuroradiology 43:353-363
9. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989-1998
10. Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64:227-237
11. Buhl R, Nabavi A, Wolff S, Hugo HH, Alfke K, Jansen O, Mehdorn HM (2007) MR spectroscopy in patients with intracranial meningiomas. Neurol Res 29:43-46
12. Chernov MF, Kasuya H, Nakaya K, Kato K, Ono Y, Yoshida S, Muragaki Y, Suzuki T, Iseki H, Kubo O, Hori T, Okada Y, Takakura K (2011) H-MRS of intracranial meningiomas: what it can add to known clinical and MRI predictors of the histopathological and biological characteristics of the tumor? Clin Neurol Neurosurg 113:202-212
13. Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ (1987) Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 164:521-526
14. Giovacchini G, Fallanca F, Landoni C, Gianolli L, Picozzi P, Attuati L, Terreni M, Picchio M, Messa C, Fazio F (2009) C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience. Clin Nucl Med 34:7-10
15. Lippitz B, Cremerius U, Mayfrank L, Bertalanffy H, Raoofi R, Weis J, Bocking A, Bull U, Gilsbach JM (1996) PET-study of intracranial meningiomas: correlation with histopathology, cellularity and proliferation rate. Acta Neurochir Suppl 65:108-111
16. Shino A, Nakasu S, Matsuda M, Handa J, Morikawa S, Inubushi T (1999) Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy. J Neurosurg 91:928-934
17. Berger G, Maziere M, Knipper R, Prenant C, Comar D (1979) Automated synthesis of 11C-labelled radiopharmaceuticals: imipramine, chlorpromazine, nicotine and methionine. Int J Appl Radiat Isot 30:393-399
18. Veninga T, Huisman H, van der Maazen RW, Huizenga H (2004) Clinical validation of the normalized mutual information method for registration of CT and MR images in radiotherapy of brain tumors. J Appl Clin Med Phys 5:66-79
19. Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, Heiss WD (2003) Methyl-[11C]- L-methionine uptake as measured by positron-emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30:868-873
20. Okita Y, Kinoshita M, Goto T, Kagawa N, Kishima H, Shimosegawa E, Hatazawa J, Hashimoto N, Yoshimine T (2010) (11)Cmethionine uptake correlates with tumor cell density rather than with microvessel density in glioma: a stereotactic image-histology comparison. Neuroimage 49:2977-2982
21. Kuratsu J, Kochi M, Ushio Y (2000) Incidence and clinical features of asymptomatic meningiomas. J Neurosurg 92:766-770
22. Nakamura M, Roser F, Michel J, Jacobs C, Samii M (2003) The natural history of incidental meningiomas. Neurosurgery 53:62-70 discussion 70-61
23. Simis A, Pires de Aguiar PH, Leite CC, Santana PA Jr, Rosemberg S, Teixeira MJ (2008) Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol 70:471-477 discussion 477
24. Iuchi T, Iwadate Y, Namba H, Osato K, Saeki N, Yamaura A, Uchida Y (1999) Glucose and methionine uptake and proliferative activity in meningiomas. Neurol Res 21:640-644
25. Astner ST, Dobrei-Ciuchendea M, Essler M, Bundschuh RA, Sai H, Schwaiger M, Molls M, Weber WA, Grosu AL (2008) Effect of 11C-methionine-positron-emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. Int J Radiat Oncol Biol Phys 72:1161-1167
26. Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, Jeong JM, Lee DS, Jung HW, Lee MC (2002) Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 29:176-182
27. Ericson K, Lilja A, Bergstrom M, Collins VP, Eriksson L, Ehrin E, von Holst H, Lundqvist H, Langsrom BB, Mosskin M (1985) Positron-emission tomography with ([11C]methyl)-L-methionine, [11C]D-glucose, and [68 Ga] EDTA in supratentorial tumors. J Comput Assist Tomogr 9:683-689
28. Grosu AL, Weber WA, Astner ST, Adam M, Krause BJ, Schwaiger M, Molls M, Nieder C (2006) 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 66:339-344
29. Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Langstrom B (2001) Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron-emission tomography. Clin Cancer Res 7:2269-2276
30. Derlon JM, Chapon F, Noel MH, Khouri S, Benali K, PetitTaboue MC, Houtteville JP, Chajari MH, Bouvard G (2000) Noninvasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 27: 778-787
31. Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, Yoshimura S, Maruyama T, Muragaki Y, Iwama T (2008) Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 29:1176-1182
32. Sadeghi N, Salmon I, Decaestecker C, Levivier M, Metens T, Wikler D, Denolin V, Rorive S, Massager N, Baleriaux D, Goldman S (2007) Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol 28:455-461
33. Principi M, Italiani M, Guiducci A, Aprile I, Muti M, Giulianelli G, Ottaviano P (2003) Perfusion MRI in the evaluation of the relationship between tumour growth, necrosis and angiogenesis in glioblastomas and grade 1 meningiomas. Neuroradiology 45: 205-211
34. Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231:305-332